Comment identifier les benzocycloheptènes ?

L'identification se fait par des techniques de spectroscopie et de chromatographie.

Quels tests sont utilisés pour les benzocycloheptènes ?

Des tests de toxicité et d'efficacité sont réalisés en laboratoire.

Les benzocycloheptènes sont-ils détectables dans le sang ?

Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques.

Y a-t-il des marqueurs spécifiques pour ces composés ?

Des marqueurs biologiques peuvent indiquer l'exposition à ces composés.

Peut-on utiliser l'imagerie pour les benzocycloheptènes ?

L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus.

Quels sont les effets secondaires des benzocycloheptènes ?

Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques.

Les benzocycloheptènes causent-ils des douleurs ?

Des douleurs peuvent survenir en cas de toxicité ou d'allergie.

Y a-t-il des symptômes neurologiques associés ?

Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître.

Peut-on observer des symptômes cutanés ?

Des éruptions cutanées peuvent survenir en cas de réaction allergique.

Les benzocycloheptènes affectent-ils le système respiratoire ?

Une exposition excessive peut entraîner des irritations respiratoires.

Comment prévenir l'exposition aux benzocycloheptènes ?

Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire.

Y a-t-il des formations pour manipuler ces composés ?

Oui, des formations spécifiques sont souvent requises pour les chercheurs.

Quels sont les risques en milieu industriel ?

Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate.

Des réglementations existent-elles pour leur usage ?

Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie.

Comment évaluer les risques d'exposition ?

Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail.

Comment traiter une intoxication aux benzocycloheptènes ?

Le traitement inclut l'élimination de l'exposition et des soins symptomatiques.

Y a-t-il des antidotes pour ces composés ?

Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes.

Quels médicaments peuvent aider en cas d'allergie ?

Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques.

Les benzocycloheptènes nécessitent-ils une hospitalisation ?

Une hospitalisation peut être nécessaire en cas de symptômes graves.

Comment gérer les effets à long terme ?

Un suivi médical régulier est recommandé pour surveiller les effets à long terme.

Quelles complications peuvent survenir avec ces composés ?

Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée.

Les benzocycloheptènes peuvent-ils causer des cancers ?

Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires.

Y a-t-il des effets sur la reproduction ?

Des effets néfastes sur la reproduction ont été observés dans certaines études animales.

Peut-on développer des allergies à long terme ?

Oui, des sensibilisations peuvent se développer avec une exposition répétée.

Les benzocycloheptènes affectent-ils le système immunitaire ?

Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections.

Qui est le plus à risque d'exposition ?

Les travailleurs en laboratoire et en industrie chimique sont les plus exposés.

L'âge influence-t-il la sensibilité ?

Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques.

Y a-t-il des prédispositions génétiques ?

Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines.

Les antécédents médicaux jouent-ils un rôle ?

Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque.

L'environnement de travail influence-t-il le risque ?

Oui, un environnement de travail mal ventilé augmente le risque d'exposition.

Benzocycloheptènes - Informations médicales vérifiées

Patterns of pregabalin prescribing in four German federal states: analysis of routine data to investigate potential misuse of pregabalin.

25 07 2022

DOI: 10.1136/bmjopen-2021-060104 PMID: 35879005

The objectives of this study were to investigate the utilisation patterns of pregabalin, to identify users potentially misusing pregabalin and to compare this group of patients to patients prescribed ... Secondary data analysis of linked data from three regional sickness funds in Germany (AOK) for the years 2014-2016.... Ambulatory and hospital care sector in four German federal states.... On the basis of routine data, patients who received at least three prescriptions of pregabalin were identified and classified into patients prescribed pregabalin as recommended and those dispensed wit... Among the 53 049 patients prescribed pregabalin, about 2% (877) were classified as potentially misusing pregabalin. The majority of this group was male and aged between 30 and 60 years. Of the patient... This study found that patients could exceed recommended doses of pregabalin by getting prescriptions from multiple physicians. Specific patients were at increased risk of potentially misusing pregabal...

Adult Analgesics, Opioid Behavior, Addictive Germany Humans +5 autres

Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.

27 08 2022

DOI: 10.1016/S0140-6736(22)01472-6 PMID: 36007534

Diabetic peripheral neuropathic pain (DPNP) is common and often distressing. Most guidelines recommend amitriptyline, duloxetine, pregabalin, or gabapentin as initial analgesic treatment for DPNP, but... OPTION-DM was a multicentre, randomised, double-blind, crossover trial in patients with DPNP with mean daily pain numerical rating scale (NRS) of 4 or higher (scale is 0-10) from 13 UK centres. Partic... Between Nov 14, 2017, and July 29, 2019, 252 patients were screened, 140 patients were randomly assigned, and 130 started a treatment pathway (with 84 completing at least two pathways) and were analys... To our knowledge, this was the largest and longest ever, head-to-head, crossover neuropathic pain trial. We showed that all three treatment pathways and monotherapies had similar analgesic efficacy. C... National Institute for Health Research (NIHR) Health Technology Assessment programme....

Amitriptyline Analgesics Cross-Over Studies Diabetes Mellitus Diabetic Neuropathies +7 autres

Lucid Dreams Associated with Pregabalin: Implications for Clinical Practice.

Sep 2022

DOI: 10.1080/15360288.2022.2081754 PMID: 35759531

Here, we describe a case of a patient with multiple myeloma who reported symptoms of lucid dreams. This patient was taking methadone for neoplasm related pain. The patient was also taking pregabalin w...

Dreams Female Humans Methadone Pain +1 autres

Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.

01 09 2022

DOI: 10.1186/s12933-022-01610-9 PMID: 36050764

Gabapentin and pregabalin are commonly prescribed medications to treat pain in patients with diabetic neuropathy. Gabapentin and pregabalin can cause fluid retention, which is hypothesized to be assoc... This retrospective cohort study used propensity score matching within patient electronic health records (EHRs) from a multicenter database with 106 million patients from 69 health care organizations i... Both gabapentin and pregabalin were associated with increased risk of 5-year adverse cardiovascular events compared with the comparison group. In patients prescribed gabapentin, the highest risk was o... In patients with diabetic neuropathy who were prescribed gabapentin and pregabalin, there is an increased risk for heart failure, myocardial infarction, peripheral vascular disease, stroke, deep venou...

Amines Analgesics Cardiovascular Diseases Cyclohexanecarboxylic Acids Diabetic Neuropathies +13 autres

Misuse of Pregabalin: a qualitative study from a patient's perspective.

12 07 2023

DOI: 10.1186/s12889-023-16051-6 PMID: 37438829

The misuse of Pregabalin has been the subject of growing concern for several years. The effects sought are multiple and it is rarely taken as a single drug. It is most frequently used together with op... A qualitative study using semi-structured interviews with 20 participants who misuse Pregabalin was conducted throughout the French-speaking region of Belgium between August 2021 and January 2022. Rec... A profile emerged, of young male users, immigrants, mainly first generation immigrants coming from North Africa. They had in common a challenging or even traumatic migration pathway and precarious liv... This study has highlighted a rare and insufficient documented profile of Pregabalin misuse: self-medication among a group of first generation immigrants, most of whom have no previous history of opioi...

Humans Male Pregabalin Qualitative Research Africa, Northern +2 autres

[Pregabalin under the prison lens. Reflections on an emerging issue].

Apr 2023

DOI: 10.1016/j.encep.2022.03.003 PMID: 35725510

The practice of medicine in prison confronts the prescriber with emerging trends in psychotropic drug misuse. We examine the increasing demand for pregabaliun, as we observe it in patients in detentio...

Humans Pregabalin Prisons Psychotropic Drugs Drug Users

Amitriptyline, Pregabalin and Duloxetine for Treatment of Painful Diabetic Peripheral Neuropathy.

22 Jun 2024

DOI: 10.33314/jnhrc.v22i01.5120 PMID: 39080958

Painful diabetic peripheral neuropathy is one of the frequent presenting complaints in diabetes and endocrine clinics. Our main objective was to compare effectiveness of three commonly prescribed drug... This was a comparative, prospective, observational study conducted among 99 diabetic patients with painful diabetic peripheral neuropathy having numeric rating pain scale ≥ 4. Thirty-three patients in... At the end of eight weeks, 84.9% in amitriptyline, 78.7% in pregabalin and 60.6% in duloxetine group had adequate pain reduction in form of mild or no pain. Among total patients, 42.5% patients had se... Amitriptyline, pregabalin and duloxetine were all associated with adequate pain reduction among patients of painful diabetic peripheral neuropathy in our study, however, amitriptyline had more favorab...

Humans Duloxetine Hydrochloride Pregabalin Amitriptyline Diabetic Neuropathies +8 autres

The anxiolytic effects of preoperative administration of pregabalin in comparison to diazepam and placebo.

15 06 2023

DOI: 10.1038/s41598-023-36616-0 PMID: 37322140

We aimed to evaluate the potential anxiolytic effects of premedication with pregabalin, compared with diazepam and placebo. We conducted this non-inferiority, double-blind, randomized controlled trial...

Humans Anti-Anxiety Agents Pregabalin Diazepam Anxiety +3 autres

Predictors of treatment response to pregabalin in unexplained or refractory chronic cough.

11 2023

DOI: 10.1016/j.rmed.2023.107396 PMID: 37657533

Patients with chronic cough (>8 weeks) often remain symptomatic after appropriate investigations and therapeutic trials. Prior research has shown a benefit in certain individuals from pregabalin, but ... The main objective of this study was to identify the demographic and clinical characteristics associated with a higher likelihood of cough improvement with a trial of pregabalin therapy.... 50 consecutive patients with chronic cough were enrolled in this prospective cohort study. Subjects were prescribed pregabalin 75 mg oral qhs for 4 weeks followed by 75 mg oral bid. Leicester Cough Qu... 56% of patients reported a LCQ total score improvement ≥1.3 (minimal clinically important difference). Responders to pregabalin therapy were more likely to have refractory (with underlying pulmonary d... This is the first study that has investigated clinical predictors of treatment response to pregabalin in chronic cough patients. Further research is needed to develop therapies for subjects who do not...

Humans Female Male Pregabalin Prospective Studies +4 autres

[Drug abuse of pregabalin - state of the situation, risks and means of control].

May 2023

DOI: 10.1016/j.pharma.2022.11.005 PMID: 36375531

Pregabalin is an anticonvulsant widely used for the treatment of epilepsy and neuropathic pain. However, there is a growing concern about its misuse, particularly among drug users and patients with su...

Humans Pregabalin Gabapentin Substance-Related Disorders Drug Overdose +1 autres

Benzocycloheptènes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Dibenzocycloheptènes

Amitriptyline

Butaclamol

Cyproheptadine

Maléate de dizocilpine

Nortriptyline

Protriptyline

Loratadine

Auteurs principaux

Jiatian Li

Xiangwen Tan

Huanfeng Jiang

Wanqing Wu

Sources (224 au total)